ndq-ex991

	Notes		As at March 31, 2016				As at December 31, 2015
ASSETS
Current assets
Cash and cash equivalents		$		96,607,988		$		106,790,202
Accounts receivable				21,775,829				21,767,746
Prepaid expenses and other assets				3,026,256				3,362,854
Inventories	3			11,694,214				10,680,885
				133,104,287				142,601,687

Non-current assets
Property and equipment, net	4			15,780,818				14,830,114
Intangible assets, net	5			18,103,388				18,539,790

Total Assets		$		166,988,493		$		175,971,591

LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities
Accounts payable and accrued liabilities		$		10,190,147		$		12,145,572
Provisions				464,580				454,579
Deferred revenue				1,492,491				1,124,808
Income taxes payable				1,600				12,500
Distribution rights payable				250,000				250,000
				12,398,818				13,987,459
Non-current liabilities
Deferred revenue				899,965				849,299
Distribution rights payable				1,509,040				1,735,012
Shareholder warrants	6			-				16,437,795

Total Liabilities		$		14,807,823		$		33,009,565

Shareholders' Equity
Share capital	9	$		337,864,162		$		322,687,011
Contributed surplus	7			17,422,057				16,400,830
Deficit				(203,105,549	)			(196,125,815	)

Total Shareholders' Equity		$		152,180,670		$		142,962,026

Total Liabilities and Shareholders' Equity		$		166,988,493		$		175,971,591

Total number of common shares outstanding	9			57,431,414				56,253,327

See accompanying notes to the interim condensed consolidated financial statements

			For the three month period ended
	Notes		March 31, 2016				March 31, 2015

Product sales		$		16,779,708		$		11,067,180
Royalty revenue				495,250				452,380
Service revenue				451,113				171,781
Total revenues				17,726,071				11,691,341
Cost of sales	3			5,068,043				4,220,144
Gross profit				12,658,028				7,471,197

Selling and distribution expenses				15,308,081				12,497,654
Research and development expenses				3,163,368				3,622,553
Administrative expenses				2,556,259				2,686,706
Total operating expenses				21,027,708				18,806,913

Loss from operations				(8,369,680	)			(11,335,716	)

Finance costs				(24,028	)			(26,048	)
Finance income				89,681				53,743
Warrants revaluation adjustment	6			1,324,293				22,630
Net loss and comprehensive loss for the period		$		(6,979,734	)	$		(11,285,391	)

Basic loss and comprehensive loss per share for the period	10	$		(0.12	)	$		(0.20	)
Diluted loss and comprehensive loss per share for the period	10	$		(0.14	)	$		(0.20	)

See accompanying notes to the interim condensed consolidated financial statements

Three months ended March 31, 2016		Share capital			Contributed surplus				Deficit				Total

As at December 31, 2015	$		322,687,011	$		16,400,830		$		(196,125,815	)	$		142,962,026
Net loss and comprehensive loss for the period			—			—				(6,979,734	)			(6,979,734	)
Exercise of options (note 9)			63,649			(26,116	)			—				37,533
Exercise of warrants (note 6)			15,113,502			—				—				15,113,502
Stock-based compensation (note 7)			—			1,047,343				—				1,047,343
As at March 31, 2016	$		337,864,162	$		17,422,057		$		(203,105,549	)	$		152,180,670


Three months ended March 31, 2015		Share capital			Contributed surplus				Deficit				Total

As at December 31, 2014	$		315,651,455	$		12,134,913		$		(165,295,336	)	$		162,491,032
Net loss and comprehensive loss for the period			—			—				(11,285,391	)			(11,285,391	)
Exercise of options (note 9)			931,321			(422,380	)			—				508,941
Exercise of warrants (note 6)			5,113,522			—				—				5,113,522
Stock-based compensation (note 7)			—			1,347,748				—				1,347,748
As at March 31, 2015	$		321,696,298	$		13,060,281		$		(176,580,727	)	$		158,175,852

See accompanying notes to the interim condensed consolidated financial statements

				For the three month period ended
	Notes			March 31, 2016				March 31, 2015
OPERATING ACTIVITIES
Net loss and comprehensive loss for the period			$		(6,979,734	)	$		(11,285,391	)
Items not affecting cash
Depreciation of property and equipment		4			1,311,122				1,216,374
Amortization of intangible assets		5			436,402				436,401
Stock-based compensation		7			1,047,343				1,347,748
Imputed interest on distribution rights payable					24,028				26,048
Shareholder warrants revaluation adjustment		6			(1,324,293	)			(22,630	)
					(5,485,132	)			(8,281,450	)
Changes in non-cash working capital
Increase in accounts receivable					(8,083	)			(1,434,355	)
Increase in inventories					(1,013,329	)			(414,813	)
Decrease in income taxes payable					(10,900	)			—
Decrease (Increase) in prepaid expenses and other assets					336,598				(986,653	)
(Decrease) increase in accounts payable and accrued liabilities and provisions					(1,951,375	)			2,050,284
Increase in deferred revenue					367,683				186,363
Net change in non-cash working capital balances related to operations					(2,279,406	)			(599,174	)

Increase in non-current deferred revenue					50,666				273,021
Cash used in operating activities					(7,713,872	)			(8,607,603	)

INVESTING ACTIVITIES
Purchase of property and equipment		4			(2,774,422	)			(1,206,099	)
Disposal of property and equipment		4			512,596				204,935
Cash used in investing activities					(2,261,826	)			(1,001,164	)

FINANCING ACTIVITIES
Proceeds from exercise of options		7			37,533				508,941
Proceeds from exercise of warrants		6			—				699,209
Repayment of distribution rights payable					(250,000	)			—
Cash provided by financing activities					(212,467	)			1,208,150

Net decrease in cash and cash equivalents					(10,188,165	)			(8,400,617	)
Net foreign exchange difference					5,951				(32,732	)
Cash and cash equivalents at beginning of period					106,790,202				141,447,544

Cash and cash equivalents at end of period			$		96,607,988		$		133,014,195

See accompanying notes to the interim condensed consolidated financial statements

Novadaq Technologies Inc. [“Novadaq” or the "Company"] was incorporated under the Canada Business Corporations Act on April 14, 2000. These consolidated financial statements include the accounts of the Company and its subsidiaries. The Company is a listed company incorporated and domiciled in Canada whose shares are publicly traded on the Toronto Stock Exchange ["TSX"] and NASDAQ. The registered office is located at 5090 Explorer Drive, Suite 202, Mississauga, Ontario, Canada. The Company develops and commercializes medical imaging and therapeutic devices for use in the operating room. The Company's proprietary imaging platform can be used to visualize blood vessels, nerves and the lymphatic system during surgical procedures. The Company is also the exclusive worldwide distributor of DermACELL® tissue products for wound and breast reconstruction surgery.

These interim condensed consolidated financial statements for the three month period ended March 31, 2016 of the Company were prepared in accordance with International Accounting Standard 34, Interim Financial Reporting ["IAS 34"] as issued by the International Accounting Standards Board ["IASB"].

The same accounting policies and methods of computation were followed in the preparation of these interim condensed consolidated financial statements as were followed in the preparation of the annual consolidated financial statements for the year ended December 31, 2015 prepared in accordance with International Financial Reporting Standards ["IFRS"] as issued by the IASB.

The interim condensed consolidated financial statements do not include all the information and disclosures required in the annual consolidated financial statements. Accordingly, these interim condensed consolidated financial statements for the three month period ended March 31, 2016 should be read together with the annual consolidated financial statements for the year ended December 31, 2015, which are available on SEDAR at www.sedar.com.

The preparation of interim condensed consolidated financial statements in accordance with IAS 34 requires the use of certain critical accounting estimates. It also requires management to exercise judgment in applying the Company’s accounting policies. The areas involving a higher degree of judgment or complexity, or areas where assumptions and estimates are significant to the financial statements are consistent with those disclosed in the notes to the annual consolidated financial statements for the year ended December 31, 2015. These interim condensed consolidated financial statements were authorized for issue by the Board of the Directors on April 27, 2016.

On December 18, 2014 the IASB issued amendments to IAS 1, Presentation of Financial Statements, as part of its initiative to improve presentation and disclosure in financial reports. The amendments are effective for annual periods beginning on or after January 1, 2016. The Company adopted these amendments in its financial statements for the annual period beginning on January 1, 2016. The adoption of the amendments did not have a material effect on the Company’s consolidated financial statements.

The IASB has issued the following new standards, which are not yet effective or adopted by the Company:

The extent of the impact of adoption of these standards has not yet been determined.

During the three month period ended March 31, 2016, $3,817,087 [three month period ended March 31, 2015 - $3,066,674] of inventory has been recognized in cost of sales.

	Medical devices			Furniture and fixtures			Computer equipment			Leasehold improvements			Total
	$			$			$			$			$
Cost:
Balance at January 1, 2016		26,737,427			474,573			1,892,522			1,611,150			30,715,672
Additions		2,552,361			14,121			81,742			126,198			2,774,422
Disposals		(1,437,942	)		—			—			—			(1,437,942	)
Balance at March 31, 2016		27,851,846			488,694			1,974,264			1,737,348			32,052,152

Depreciation:
Balance at January 1, 2016		(13,522,500	)		(438,942	)		(1,648,587	)		(275,529	)		(15,885,558	)
Depreciation		(1,215,536	)		(5,713	)		(52,168	)		(37,705	)		(1,311,122	)
Disposals		925,346			—			—			—			925,346
Balance at March 31, 2016		(13,812,690	)		(444,655	)		(1,700,755	)		(313,234	)		(16,271,334	)

Net book value at March 31, 2016		14,039,156			44,039			273,509			1,424,114			15,780,818

	Medical devices			Furniture and fixtures			Computer equipment			Leasehold improvements			Total
	$			$			$			$			$
Cost:
Balance at January 1, 2015		24,913,546			450,791			1,663,792			294,180			27,322,309
Additions		6,488,498			23,782			228,730			1,316,970			8,057,980
Disposals		(4,664,617	)		—			—			—			(4,664,617	)
Balance at December 31, 2015		26,737,427			474,573			1,892,522			1,611,150			30,715,672

Depreciation:
Balance at January 1, 2015		(11,557,846	)		(419,792	)		(1,448,474	)		(248,378	)		(13,674,490	)
Depreciation		(4,888,278	)		(19,150	)		(200,113	)		(27,151	)		(5,134,692	)
Disposals		2,923,624			—			—			—			2,923,624
Balance at December 31, 2015		(13,522,500	)		(438,942	)		(1,648,587	)		(275,529	)		(15,885,558	)

Net book value at December 31, 2015		13,214,927			35,631			243,935			1,335,621			14,830,114

As at March 31, 2016, medical devices includes construction-in-progress of $7,166,385 [December 31, 2015 - $6,136,442] which are not being depreciated. Depreciation will commence when the devices are placed at medical institutions.

Intangible assets include licenses, patent rights and distribution rights as summarized below:

	Licenses			Patent rights			Distribution rights			Total
	$			$			$			$
Cost:
Balance at January 1, 2016		5,913,642			14,920,855			7,880,819			28,715,316
Additions		—			—			—			—
Balance at March 31, 2016		5,913,642			14,920,855			7,880,819			28,715,316

Amortization:
Balance at January 1, 2016		(5,913,642	)		(3,426,306	)		(835,578	)		(10,175,526	)
Amortization		—			(239,383	)		(197,019	)		(436,402	)
Balance at March 31, 2016		(5,913,642	)		(3,665,689	)		(1,032,597	)		(10,611,928	)
Net book value at March 31, 2016		—			11,255,166			6,848,222			18,103,388

	Licenses			Patent rights			Distribution rights			Total
	$			$			$			$
Cost:
Balance at January 1, 2015		5,913,642			14,920,855			7,880,819			28,715,316
Additions		—			—			—			—
Balance at December 31, 2015		5,913,642			14,920,855			7,880,819			28,715,316

Amortization:
Balance at January 1, 2015		(5,913,642	)		(2,504,258	)		(47,501	)		(8,465,401	)
Amortization		—			(922,048	)		(788,077	)		(1,710,125	)
Balance at December 31, 2015		(5,913,642	)		(3,426,306	)		(835,578	)		(10,175,526	)
Net book value at December 31, 2015		—			11,494,549			7,045,241			18,539,790

	February 2010						March 2011
	Shareholder Warrants						Shareholder Warrants						Total
	#			$			#			$			$

December 31, 2014		290,089			4,080,925			1,561,515			21,792,160			25,873,085
Exercised		(290,089	)		(4,414,313	)		—			—			(4,414,313	)
Revaluation		—			333,388			—			(5,354,365	)		(5,020,977	)
December 31, 2015		—			—			1,561,515			16,437,795			16,437,795
Exercised		—			—			(1,561,515	)		(15,113,502	)		(15,113,502	)
Revaluation		—			—			—			(1,324,293	)		(1,324,293	)
March 31, 2016		—			—			—			—			—

On March 24, 2011, the Company closed a private placement of $14,280,240, net of transaction costs of $998,207, in exchange for 4,731,864 units at a price of CDN $3.17 per unit. Each unit consists of one common share and 0.45 of a warrant, representing 2,129,339 warrants. Each warrant has a five-year term and is exercisable either for one common share at an exercise price of CDN $3.18 or on a cashless basis in accordance with the Warrant Agreement. Because such warrants were denominated in Canadian dollars [a currency different from the Company's functional currency], they are recognized as a financial liability at fair value through profit or loss. In determining the initial fair value of the warrants, the Company used the Black‑Scholes option pricing model with the following assumptions: weighted average volatility rate of 66%; risk-free interest rate of 1.98%; expected life of five years; and an exchange rate of 1.026. The value of $3,695,513, net of transaction costs, was established on March 24, 2011 and subsequently revalued on December 31, 2011 utilizing the Black‑Scholes option pricing model with the following assumptions: volatility rate of 64%; risk‑free interest rate of 1.85%; expected life of 4.23 years; and exchange rate of 0.980. The fair value of the warrants before transaction costs were initially U.S. $1.86 per warrant at issuance and at December 31, 2015 were valued at U.S. $10.53 per warrant.

During the three month period ended March 31, 2016, the remaining warrants of 1,561,515 were exercised on a cashless basis whereby the Company issued 1,166,753 common shares from treasury [see Note 9]. Upon conversion of the warrants to common shares, the warrants were de-recognized and the fair value of the warrants of $15,113,502 was recognized as share capital.

In February 2010, the Company closed a private placement of U.S. $6,610,157, net of transaction costs of $511,180, in which 3,049,205 units at CDN $2.43 per unit were issued. Each unit is comprised of one common share and one-fifth of a warrant. Each warrant has a five-year term and is exercisable for one common share at an exercise price of CDN $3.00. Because such

warrants were denominated in Canadian dollars [a currency different from the Company’s functional currency], they are recognized as a financial liability at fair value through profit or loss. In determining the initial fair value of the shareholder warrants, the Company used the Black‑Scholes option pricing model with the following assumptions: volatility rate of 69%; risk-free interest rate of 1.88%; expected life of 5 years for shareholder warrants and 3 years for broker warrants; and exchange rate of 0.960. Shareholder warrants were initially valued at U.S. $1.47 and revalued at December 31, 2014 at U.S. $14.07 per warrant.

During the three month period ended March 31, 2015, the remaining warrants of 290,089 were exercised [see Note 9] for cash consideration of $699,209.

On March 29, 2005, the Company established an amended stock option plan [the "Plan"] for the employees, directors, senior officers and consultants of the Company and any affiliate of the Company which governs all options issued under its previously existing stock option plans and future option grants made under the Plan. On May 15, 2008, the shareholders at the annual and special meeting approved the "Second Amended and Restated Stock Option Plan", which was an amendment to the Plan.

Under the Plan, options to purchase common shares of the Company may be granted by the Board of Directors. Options granted under the Plan will have an exercise price of not less than the volume-weighted average trading price of the common shares for the five trading days preceding the date on which the options are granted. The maximum aggregate number of common shares which may be subject to options under the Plan is 10% of the common shares of the Company outstanding from time to time.

Options granted under the Plan will generally vest over a three-year period and may be exercised in whole or in part at any time as follows: 33% on or after the first anniversary of the grant date, 67% on or after the second anniversary of the grant date and 100% on or after the third anniversary of the grant date. Options expire on the tenth anniversary of the grant date. Any options not exercised prior to the expiry date will become null and void. In connection with certain change of control transactions, including a take-over bid, merger or other structured acquisition, the Board of Directors may accelerate the vesting date of all unvested options such that all optionees will be entitled to exercise their full allocation of options and in certain circumstances, where such optionee's employment is terminated in connection with such transaction, such accelerated vesting will be automatic. Options granted under the Plan will terminate on the earlier of the expiration of the option or 180 days following the death of the optionee or termination of the optionee's employment because of permanent disability, as a result of termination of the optionee's employment because of retirement of an optionee or as a result of such optionee ceasing to be a director, or 30 days following termination of an optionee.

The stock‑based compensation cost, related to options, that has been recognized for the three month period ended March 31, 2016 and included in the respective function line in the consolidated statements of loss and comprehensive loss is $1,016,256 [three month period ended March 31, 2015 - $1,347,748] with a corresponding increase to contributed surplus.

A summary of the options outstanding as at March 31, 2016 and December 31, 2015 under the Plan are presented below (all weighted average exercise prices expressed in CDN dollars):

	For the three month period ended					For the year ended
	March 31, 2016					December 31, 2015
	Number outstanding			Weighted average exercise price		Number outstanding			Weighted average exercise price
	#			$		#			$

Options outstanding, beginning of period		3,894,805			12.25		3,691,962			11.32
Options granted		134,500			12.81		1,085,000			14.17
Options exercised		(11,334	)		4.40		(390,670	)		3.68
Options cancelled		(31,223	)		18.84		(95,932	)		12.24
Options forfeited		(67,943	)		17.22		(395,555	)		17.58
Options outstanding, end of period		3,918,805			12.15		3,894,805			12.25

Options exercisable, end of period		2,028,247			8.36		1,944,472			8.88

The Company uses the Black-Scholes option pricing model to determine the fair value of options. On February 17, 2016, the Company issued 134,500 options under the Plan. For the three month period ended March 31, 2016, the Company used the following assumptions to determine the fair value of each of the options granted:

The expected life of the options is based on historical data and current expectations and is not necessarily indicative of exercise patterns that may occur. The expected volatility reflects the assumption that the historical volatility over a period similar to the expected life of the options is indicative of future trends, which may also not necessarily be the actual outcome.

There have been no modifications to the Plan during the periods presented in the interim condensed consolidated financial statements.

On April 7, 2015 the Company established a long-term incentive plan comprised of Restricted Share Units (RSUs) and Deferred Share Units (DSUs).

In connection with certain change of control transactions, including a take-over bid, merger or other structured acquisition, the Board of Directors may accelerate the vesting date of all unvested RSUs and DSUs such that all participants will be entitled to settle their full allocation of RSUs and/or DSUs and in certain circumstances, where such participant's employment is terminated in connection with such transaction, such accelerated vesting will be automatic.

RSUs granted under the plan will generally vest over a three-year period and may be settled in whole or in part at any time as follows: one-third on or after the first anniversary of the grant date, one third on or after the second anniversary of the grant date, one third on or after the third anniversary of the grant date, and in certain cases, if specified performance objectives are met as determined by the Board of Directors. RSUs granted under the plan will expire upon the termination of the participant’s employment, retirement, permanent disability or death. RSUs must be settled no later than December 31 of the third calendar year following the year in which the services giving rise to the award were rendered. RSUs may be settled for their cash equivalent or by the issuance of the Company’s common shares, subject to discretion of the Board of Directors. Each RSU is the equivalent of one Novadaq common share. The fair value for each RSU granted, which approximates the market value of a Novadaq common share at the date of grant, is recognized over the term of the vesting period, with a corresponding increase to contributed surplus based on the number of RSUs expected to vest.

The table below is a summary of the RSUs outstanding as at March 31, 2016 and December 31, 2015:

The stock‑based compensation cost that has been recognized for the three month period ended March 31, 2016 and included in the respective function lines in the consolidated statements of loss and comprehensive loss is $31,087 [three month period ended March 31, 2015 – nil].

DSUs granted under the plan may be settled when the participant ceases to be a member of the Board of Directors. The participant may elect to settle DSUs for their cash equivalent or for the issuance of the Company’s common shares. Outstanding DSUs are initially recorded as a liability on the statement of financial position, measured at the awards’ fair value on the date of grant based on the market price of the Company’s common shares, with a corresponding charge to operating costs. If an award’s fair value changes after it has been granted and before the settlement date, the resulting change in the liability is recorded as a charge to operating costs in the period that the change occurs.

There were no DSUs granted during the three month periods ended March 31, 2016 and March 31, 2015.

There have been no modifications to the long-term incentive plan during the three month periods ending March 31, 2016 and March 31, 2015.

Set out below is a comparison by type of the carrying amounts and fair values of the Company's recognized financial instruments that are recorded in the consolidated statements of financial position:

	March 31, 2016				December 31, 2015
	Carrying amount		Fair value		Carrying amount		Fair value
	$		$		$		$
Financial assets
Held-for-trading
Cash and cash equivalents		96,607,988		96,607,988		106,790,202		106,790,202
Loans and receivables
Accounts receivable		21,775,829		21,775,829		21,767,746		21,767,746
		118,383,817		118,383,817		128,557,948		128,557,948

Financial liabilities
Derivative financial liabilities at fair value through profit or loss
Shareholder warrants	-	-	16,437,795	16,437,795
Other financial liabilities
Distribution rights payable	1,759,040	1,759,040	1,985,012	1,985,012
Accounts payable and accrued liabilities	10,190,147	10,190,147	12,145,572	12,145,572
	11,949,187	11,949,187	30,568,379	30,568,379

The fair values of the financial assets and liabilities are shown at the amount at which the instrument could be exchanged in a current transaction between willing parties, other than in a forced or liquidation sale.

The Company uses the following hierarchy for determining and disclosing the fair value of financial instruments by valuation technique:

The fair value hierarchy of financial instruments measured at fair value on the consolidated statements of financial position is as follows:

	March 31, 2016						December 31, 2015
	Level 1		Level 2		Level 3		Level 1		Level 2		Level 3
	$		$		$		$		$		$
Financial assets
Cash and cash equivalents		96,607,988		-		-		106,790,202		-		-

Financial liabilities
Shareholder warrants		-		-		-		-		16,437,795		-

During the reporting periods, there were no transfers between Level 1 and Level 2 fair value measurements.

As at March 31, 2016, one customer had an accounts receivable balance exceeding 10% of total accounts receivable [December 31, 2015 – one customer]. Concentration of this customer comprised 33% of total accounts receivable as at March 31, 2016 as compared to 21% as at December 31, 2015.

The Company has authorized share capital as follows: common shares - unlimited, no par value; preference shares - unlimited, no par value, issuable in one or more series.

Basic loss per share amounts are calculated by dividing net loss for the period attributable to ordinary equity holders by the weighted average number of ordinary shares outstanding during the period. Diluted loss per share amounts are calculated by dividing the net loss attributable to ordinary equity holders by the weighted average number of ordinary shares outstanding during the period plus the weighted average number of ordinary shares that would be issued on conversion of all of the dilutive potential ordinary shares into ordinary shares.

The following reflects the loss and share data used in the basic and diluted loss per share computations:

There have been no other transactions involving ordinary shares or potential ordinary shares between the reporting date and the date of completion of these interim condensed consolidated financial statements.

The conversion of outstanding stock options or RSUs has not been included in the determination of basic and diluted loss per share as to do so would have been anti‑dilutive.

The Company’s business activities are conducted through one segment which consists of medical devices and related products and services. Segment performance is based on gross margin and is measured consistently with the gross margin of the consolidated financial statements since there is only one segment.

For the three month period ended March 31, 2016, there were sales to one customer that exceeded 10% of total revenue [three month period ended March 31 2015 - none]. Concentration of this customer comprised of 29% of total revenue for the three month period ended March 31, 2016.

	March 31, 2016		December 31, 2015
	$		$
Raw materials		8,483,923		7,943,924
Medical devices, software and parts		3,144,196		2,661,247
TMR kits		66,095		75,714
		11,694,214		10,680,885

	February 17, 2016 Grant
	Employees
Weighted average volatility rate		52%
Expected dividend yield	Nil
Weighted average expected life (in years)		3.7
Weighted average interest rate	0.57%
Exchange rate		0.7297
Fair Value per option	$	3.55

	For the three month period ended			For the year ended
	March 31, 2016			December 31, 2015
	Number outstanding			Number outstanding
	#			#

RSU's outstanding, beginning of period		29,302			-
RSU's granted		-			30,302
RSU's forfeited		(1,077	)		(1,000	)
RSU's outstanding, end of period		28,225			29,302

	For the three month period ended
	March 31, 2016			March 31, 2015
Net loss and comprehensive loss attributable to shareholders for basic loss per share		(6,979,734	)		(11,285,391	)
Net loss and comprehensive loss attributable to shareholders for diluted loss per share		(8,304,027	)		(11,285,391	)
Weighted average number of shares for basic loss per share		56,464,036			55,913,270
Weighted average number of shares for diluted loss per share		57,474,701			55,913,270

	March 31, 2016		December 31, 2015
	$		$

Canada		8,837,299		7,955,468
United States		5,821,457		5,765,396
Outside North America		1,122,062		1,109,250
Total		15,780,818		14,830,114

	Common shares
	#		$

Balance at December 31, 2014		55,572,568		315,651,455
Exercise of stock options		390,670		1,922,034
Exercise of shareholder warrants		290,089		5,113,522
Balance at December 31, 2015		56,253,327		322,687,011
Exercise of stock options		11,334		63,649
Exercise of shareholder warrants		1,166,753		15,113,502
Balance at March 31, 2016		57,431,414		337,864,162